Surveillance of Bromocriptine in Pregnancy

Abstract

Information was collected on the outcome of 1,410 pregnancies in 1,335 women to whom bromocriptine mesylate (Parlodel) had been given, primarily in the early weeks of pregnancy. These Pregnancies resulted in 197 early terminations (14%) (including 25 induced abortions [1.8%) and in 1,213 births (86%). The incidence rate of spontaneous abortions (11.1%), extrauterine pregnancies (0.9%), and minor (2.5%) and major (1.0%) malformations is comparable with that quoted for normal populations, and the incidence of twin pregnancies (1.8%) is slightly but not significantly raised, if correction is made for concomitant therapy with other agents inducing ovulation. The data suggest that the intake of bromocriptine during pregnancy is not associated with an increased risk to the fetus.

Pregnancy in acromegaly: a one-center experience

“…It is common politics (1) to stop any GH-suppressive treatment, as we did, after confirmation of pregnancy, even though cases were reported in whom medications were continued throughout pregnancy. While bromocriptine is regarded as safe even during pregnancy, due to its widespread use in patients affected by prolactinoma (12), data inpregnancy are still scarce about SA that became in recent years the mainstay of medical treatment in Figure 1 Growth hormone (expressed as microgram/liter with squares and continuous line on the left axis), insulin-like growth factor-I (expressed as percentage of the upper limit of normal range with diamonds and broken line on the right axis), and prolactin levels (expressed as microgram/liter with circles and dotted line on the right axis) before pregnancy, during the first, second, and third trimester, and 1-5 months after delivery are depicted for each pregnancy (ID as in Table 2 in the upper part of each panel). Please note that scale is different in different panels.…”

Peripartum Cardiomyopathy

“…56 However, enthusiasm for these early results has been tempered by the small size of the unblinded, randomized, controlled trial study, the surprisingly frequent adverse outcomes in the control arm of the study, and the potential danger of using bromocriptine in the peripartum period. Bromocriptine was deemed in 1982 to be safe to the fetus, 57 but its approval for the suppression of lactation was withdrawn in the United States in 1995 as a result of concerns about adverse maternal vascular events. 58 Moreover, potential harm to the newborn by suppression of lactation must be considered, in particular in the developing world where undernutrition and unsafe water supplies account for the majority of childhood mortality, rendering reliance on breast milk critical.…”

Follow-Up of Children Born of Bromocriptine-Treated Mothers

“…and it appears that there is no risk of fetal malfor mation due to treatment (and/or the underly ing pathology) [4], Several authors have re ported the absence of any abnormality in child development; however follow-up is still relatively limited (first years of life), espe cially in cases where the administration of BC was stopped immediately after the diag nosis of pregnancy [5,6].…”